التفاصيل البيبلوغرافية
| العنوان: |
Ethacridine inhibits SARS-CoV-2 by inactivating viral particles |
| المؤلفون: |
Li, Xiaoquan, Lidsky, Peter V., Xiao, Yinghong, Wu, Chien-Ting, Garcia-Knight, Miguel, Yang, Junjiao, Nakayama, Tsuguhisa, Nayak, Jayakar V., Jackson, Peter K., Andino, Raul, Shu, Xiaokun |
| المساهمون: |
Subbarao, Kanta, National Institutes of Health, Program for Breakthrough Biomedical Research, Bill and Melinda Gates Foundation, Defense Advanced Research Projects Agency |
| المصدر: |
PLOS Pathogens ; volume 17, issue 9, page e1009898 ; ISSN 1553-7374 |
| بيانات النشر: |
Public Library of Science (PLoS) |
| سنة النشر: |
2021 |
| المجموعة: |
PLOS Publications (via CrossRef) |
| الوصف: |
The respiratory disease COVID-19 is caused by the coronavirus SARS-CoV-2. Here we report the discovery of ethacridine as a potent drug against SARS-CoV-2 (EC 50 ~ 0.08 μ M). Ethacridine was identified via high-throughput screening of an FDA-approved drug library in living cells using a fluorescence assay. Plaque assays, RT-PCR and immunofluorescence imaging at various stages of viral infection demonstrate that the main mode of action of ethacridine is through inactivation of viral particles, preventing their binding to the host cells. Consistently, ethacridine is effective in various cell types, including primary human nasal epithelial cells that are cultured in an air-liquid interface. Taken together, our work identifies a promising, potent, and new use of the old drug via a distinct mode of action for inhibiting SARS-CoV-2. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1371/journal.ppat.1009898 |
| الإتاحة: |
https://doi.org/10.1371/journal.ppat.1009898Test |
| حقوق: |
http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: |
edsbas.3FD30C6B |
| قاعدة البيانات: |
BASE |
